To be held on Saturday, November 15, 2008 at the TradeWinds Island Hotel
in St. Pete Beach, Florida, USA.

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The University of Rochester School of Medicine and Dentistry designates this educational activity for a maximum of 3.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The Symposium consists of three keynote speakers and four platform presentations by the following individuals with allotted time for questions and answers after each presenter.

8:00 am – 9:00 am	Poster Setup & Viewing, Continental Breakfast
9:00 am – 9:05 am	Introduction (Jang-Ho Cha, MD, PhD, Symposium Chair; Richard Myers, PhD, Symposium Co-Chair)
9:05 am – 9:45 am	Keynote Presentation I Charles Sabine, BA, NBC News Correspondent “Unmet Clinical Research Needs for Persons with Pre-Manifest Huntington Disease”
9:45 am – 10:00 am	Platform Presentation I Andrew Churchyard, MD, Huntington Service, Caufield, Australia "Lifestyle Activity and the Onset of Huntington Disease"
10:00 am – 10:15 am	Platform Presentation II Elizabeth Aylward, PhD, University of Washington, Seattle, WA "Longitudinal Structural MRI Data from PREDICT-HD: Striatal and Cortical Changes in Pre-Clinical HD"
10:15 am – 11:30 am	Break/Poster Viewing (Snack & Beverage)
11:30 am – 12:10 pm	Keynote Presentation II:  Lewis Maltby, JD, President, National Workrights Institute "GINA: Public Policy, Private Protection and Implications for Huntington Disease"
12:10 pm – 12:25 pm	Platform Presentation III Kathleen Poston, MD, The Feinstein Institute for Medical Research, Manhasset, NY "Loss of Striatal Dopaminergic Function and Thalmic Compensatory Mechanism during Phenoconversion of Preclinical Huntington's Disease"
12:25 pm – 12:40 pm	Platform Presentation IV Karl Kieburtz, MD, University of Rochester, Rochester, NY "Dimebon in Mild-to-Moderate Huntington's Disease: A Multicenter, Phase 2, Randomized, Placebo-Controlled Trial (DIMOND)"
12:40 pm – 1:20 pm	Keynote Presentation III:  Russell Katz, MD, Director, Division of Neurology Products, FDA “The Pathway Forward for Development of New Treatments for Manifest and Premanifest Huntington Disease”
1:20 pm	Adjourn

POSTER SESSION
Posters will be staffed from 8:00 – 9:00 AM and 10:15 – 11:30 AM in the Pavilion.

Poster 1
Survey of Clinical Trial Interest and Literacy in Huntington Support Groups: Northwest Pilot Project.
L. Veatch Goodman,1 J. Giuliano,2 and D. Lovecky.3 
1HD Drug Works, Seattle, WA, USA, 2CHDI Foundation, Princeton, NJ, USA and 3Huntington’s Disease Society of America, NY, NY, USA.

Poster 2
The Involvement of Children in COHORT.
K. Quaid1 and L. Dure.2 
1Indiana University School of Medicine, Indianapolis IN, USA and 2The University of Alabama at Birmingham, Birmingham, AL, USA.

Poster 3
An Examination of Actual and Potential Discrimination of Individuals at Risk of Huntington's Disease: An Analysis of the RESPOND-HD Data from Australia (Site 144).
A. Goh,1 O. Yastrubetskaya,1,2 and E. Chiu.1,2 
1Academic Unit for The Psychiatry of Old Age, The University of Melbourne, Victoria, Australia and 2St Vincent’s Aged Psychiatry Service, Melbourne, Victoria, Australia.

Poster 4
The Functional Rating Scale Taskforce for Pre-Huntington’s Disease: An Empirically-Driven Initiative for New Scale Development.
K. Evans,1 K. Anderson,2 B. Borowsky,3 K. Duff,4 J. Giuliano,3 M. Guttman,5 A. Ho,6 D. Langbehn,4 J.Paulsen,4 T. Sills,1 A. Vaccarino,1 D. Van Kammen ,3 and the FuRST-pHD and PREDICT-HD investigators and coordinators of the HSG. 
1Ontario Cancer Biomarker Network, Toronto, ON Canada, 2University of Maryland, Baltimore, MD USA, 3CHDI Foundation, Princeton, NJ USA, 4University of Iowa, Iowa City, IA, USA, 5The Center for Movement Disorders, Markham, ON Canada and 6University of Reading, Reading, UK.

Poster 5
An Item Response Analysis of Depressive Symptomatology in pre-Huntington Disease.
A.Vaccarino,1 K. Anderson,2 B. Borowsky,3 K. Duff,4 K. Evans,1 J. Giuliano,3 M. Guttman,5 A. Ho,6 D. Langbehn,4 J. Paulsen,4 T. Sills,1 D. Van Kammen,3 and the FuRST-pHD and PREDICT-HD investigators and coordinators of the HSG. 
1Ontario Cancer Biomarker Network, Toronto, ON Canada, 2University of Maryland, Baltimore, MD, USA, 3CHDI Foundation, Princeton, NJ, USA, 4University of Iowa, Iowa City, IA, USA, 5The Center for Movement Disorders, Markham, ON Canada, and 6University of Reading, Reading, UK.

Poster 6
Triglyceride-Lowering Effects of EPA in Individuals with Huntington Disease.
R.C. Block,1 E.R. Dorsey,2 C.A. Beck,3 and I. Shoulson2 for the Huntington Study Group TREND-HD Investigators
1Department of Community and Preventive Medicine and Preventive Cardiology Unit, University of Rochester School of Medicine and Dentistry Rochester, NY, USA, 2Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, and 3Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.

Poster 7
Memory for Temporal Sequences for the Early Detection of Cognitive Changes in Preclinical Huntington’s Disease.
E. Pirogovsky,1 B. Bartlett,2 A. Callazo,2 J. Goldstein,3 G. Peavy,3 M. Jacobson,4,5 J. Corey-Bloom,3,5 and P. Gilbert.1 
1SDSU-UCSD Joint Doctoral Program in Clinical Psychology, San Diego, CA, USA, 2Department of Psychology, UCSD, San Diego, CA,USA,, 3Department of Neurosciences, UCSD, San Diego, CA, USA, 4Department of Psychiatry, UCSD, San Diego, CA, USA, and 5Veterans Affairs, San Diego Health Care System, San Diego, CA, USA.

Poster 8
A Comparison of Two Brief Cognitive Instruments in Huntington Disease (HD).
J. Corey-Bloom,1,3 J.L. Goldstein,1 S. Lessig,1,3 G.M Peavy,1 and M.W. Jacobson.2,3 
1Department of Neurosciences, UCSD, San Diego, CA,USA, 2Department of Psychiatry, UCSD, San Diego, CA, USA and 3Veterans Affairs, San Diego Health Care System, San Diego, CA, USA.

Poster 9
Corticostriatal Abnormalities in HD: a combined Magnetic Resonance Spectroscopy and Diffusion Tensor Imaging Study.
K.E. Weaver, T.L. Richards, O. Liang, and E.H. Aylward. 
Department of Radiology, University of Washington, School of Medicine, Seattle, WA, USA.

Poster 10
A Randomized, Controlled Trial of Atomoxetine for Cognitive Dysfunction in Early Huntington’s Disease.
L.J. Beglinger,1 W.H. Adams,1 H. Paulson,2 J.G. Fiedorowicz,1 D.R. Langbehn,1 K.Duff,1 A. Leserman,1 and J.S. Paulsen.1 
1University of Iowa, Iowa City, IA,USA and 2University of Michigan, Ann Arbor, MI, USA.

Poster 11
Motor Symptom-related Metabolic Network in Huntington’s Disease.
A. Feigin,1,2 C. Tang,1 K.L. Poston,1 Y. Ma,1,2 M. Guttman,3 J.S. Paulsen,4 V. Dhawan,1,2 and D. Eidelberg.1,2
1Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System, Manhasset, NY, USA, 2Department of Neurology, North Shore University Hospital and New York University School of Medicine, NY, NY, USA, 3Department of Neurology, University of Toronto, Toronto, Canada and 4Department of Neurology, University of Iowa, Des Moines, IA, USA.

Poster 12
A Metabolic Network Associated With the Progression of Preclinical Huntington’s Disease: Application of the Ordinal Trends Analysis to a Longitudinal PET Study.
C. Tang,1 A. Feigin,1,2 K.L. Poston,1 Y. Ma,1,2 M. Guttman,3 J.S. Paulsen,4 V.Dhawan,1,2 and D. Eidelberg.1,2
1Center for Neurosciences, The Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System, Manhasset, NY, USA, 2Department of Neurology, North Shore University Hospital and New York University School of Medicine, NY, NY, USA, 3Department of Neurology, University of Toronto, Toronto, Canada and 4Department of Neurology, University of Iowa, Des Moines, IA, USA.

Poster 13
Early Diagnosis of Mitochondrial Dysfunction in Huntington’s Disease in Vivo.
K.E. Conley, S. Jubrias, C. Amara, E. Shankland, D.J. Marcinek and E. Aylward. 
University of Washington Medical Center, Seattle, WA, USA.

Poster 14
Earliest Functional Declines in Huntington’s Disease.
J.F. O’Rourke, L.J. Beglinger, C. Wang, D.R. Langbehn, K. Duff, and J.S. Paulsen. 
University of Iowa, Iowa City, IA, USA.

Poster 15
Predicting cognitive decline: Another method for stratifying samples?
K. Duff,1 L.J. Beglinger,1 J.C. Stout,2 J.S. Paulsen,1 and the Investigators of PREDICT-HD. 
1University of Iowa, Iowa City, IA, USA and 2Monash University, Melbourne, Australia.

Poster 16
Antidepressant Use in PREDICT-HD: Patterns of Use Relevant to “Naturalistic” Drug Studies.
K. Rowe, L. Beglinger, C. Wang, D. Langbehn, K. Duff and J. Paulsen. 
University of Iowa, Iowa City, IA, USA.

Poster 17
Lifestyle Activity and the Age of Onset of Huntington Disease.
K. Trembath,1 A. Churchyard,2 Z. Horton,1 L. Tippett,3 V. Hogg,3 R. Roxburgh,4 D. Velakoulis,5 V Collins,1,6 M. Delatycki.1,6 
1Bruce Lefroy Centre for Genetic Health Research, Murdoch Childrens Research Institute, Royal Children’s Hospital, Parkville 3052, Australia, 2Huntington Service, Calvary Healthcare Bethlehem, Caulfield 3162, Australia, 3Department of Psychology, The University of Auckland, Auckland 1142, New Zealand, 4Department of Neurology, Auckland City Hospital, Auckland, New Zealand, 5Neuropsychiatry Unit, Royal Melbourne Hospital, Parkville 3050, Australia, and 6Genetic Health Services Victoria, Royal Children’s Hospital, Parkville 3052, Australia.

Late-Breaking Research

Poster 18
The Effects of Assistive Devices on Gait Measures in Huntington’s Disease.
A.D. Kloos,1 D.A. Kegelmeyer,1 S.K. Kostyk.2 
1The Ohio State University, Physical Therapy Division, Columbus, Ohio, USA and 2The Ohio State University, Departments of Neurology and Neuroscience, Columbus, Ohio, USA.

Poster 19
Basal Ganglia Pathology in Preclinical and Early Symptomatic Huntington’s Disease: Diffusion Tensor Imaging, Magnetic Resonance Spectroscopy and Volumetric Measures- Which Imaging Modality is More Sensitive?
P. Chua,1 P. Desmond,3,5 S. Christensen,3 C. Steward,5 D. Velakoulis,2,4 F. Judd,4 E. Chiu,4 J. Lloyd,2 and B. Tress.5 
1Dept of Psychological Medicine- Monash University, Clayton, Victoria, Australia, 2 Melbourne Neuropsychiatry Centre- Royal Melbourne Hospital, Parkville,Victoria, Australia, 3Dept of Radiology- Royal Melbourne Hospital, Parkville, Victoria, Australia, 4Dept of Psychiatry- University of Melbourne, Parkville, Victoria, Australia and 5Dept of Radiology- University of Melbourne, Parkville, Victoria, Australia.

Poster 20
Music, Meditation and Huntington’s Disease.
M. Pugliese, P. Phan, and J. Sanchez-Ramos. 
Huntington’s Disease Center of Excellence at USF, Tampa, Florida, USA.

Poster 21
Insurance Ownership and Genetic Risk.
E. Oster, PhD,1 J. Bausch, BS,3 A. Shinaman, JD,2 E. Kayson, MS, RNC,2 D. Oakes, PhD,3 I. Shoulson, MD,2 K. Quaid, PhD4 and E. R. Dorsey, MD, MBA2 for the Huntington Study Group PHAROS Investigators. 
1Department of Economics, The University of Chicago, Chicago, IL, USA, 2Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA, 3Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, USA and 4Department of Medical and Molecular Genetics, Indiana University, Indianapolis, IN, USA.

Poster 22
Cooperative Huntington Observational Research Trial (COHORT): Baseline Mental Health Risks.
Huntington Study Group COHORT Investigators.

Poster 23
Characterization of Frontal Lobe Behavioral Syndromes in Huntington’s Disease (HD).
L. Oelke, L. Butterfield, C. Cimino, J. Sanchez-Ramos, M. McCall, M. Pugliese, L. Ling, B. Stell and J. Annis. 
University of South Florida, Tampa, Florida, USA.

Poster 24
Expert Treatment Preferences for the Motor, Mood, and Behavioral Symptoms of Huntington’s Disease.
L. Veatch Goodman,1 J. Cha2 and P. Como.3 
1HD Drug Works, Seattle, WA, USA, 2Massachusetts General Hospital, Boston, MA, USA and 3University of Rochester, Rochester, NY, USA.